ChemicalBook CAS DataBase List 6325-13-9

6325-13-9

Name	Butanoic acid, 4,4'-thiobis-, bis[[(2-hydroxyphenyl)methylene]hydrazide] (9CI)
CAS	6325-13-9
Molecular Formula	C22H26N4O4S
Molecular Weight	442.53
MOL File	6325-13-9.mol

Chemical Properties

density	1.25±0.1 g/cm3(Predicted)
form	Solid
pka	8.29±0.35(Predicted)
color	White to off-white

Hazard Information

Uses

Nrf2-IN-3 (Compound R16) is a small-molecule NRF2 inhibitor and increases reactive oxygen species (ROS) production. Nrf2-IN-3 selectively binds KEAP1 mutants and restores their NRF2-inhibitory function by repairing the disrupted KEAP1/NRF2 interactions, leading to proteasome-dependent NRF2 degradation in cells. Nrf2-IN-3 sensitizes KEAP1-mutated tumor cells to Cisplatin (HY-17394), Gefitinib (HY-50895), and KEAP1 G333C-mutated xenograft to Cisplatin [1].

in vivo

Nrf2-IN-3 (110 mg/kg i.p. daily for 5 days per week for six weeks) inhibits tumor growth and selectively sensitizes mKEAP1 A549ctl xenograft to Cisplatin (HY-17394)^[1].

Animal Model:	Palpable tumors were generated by subcutaneous injection of a million A549ctl or A549(WT-KEAP1) cells in the flank of NOD-SCID mice^[1].
Dosage:	110 mg/kg for Nrf2-IN-3 and 2 mg/kg for Cisplatin.
Administration:	Combination of Cisplatin (2 mg/kg) and Nrf2-IN-3 (110 mg/kg). The treatment started on day 18 after subcutaneous injection of A549ctl cells. Mice were treated i.p. with R16 at 110 mg/kg daily for 5 consecutive days per week, Cisplatin at 2 mg/kg twice per week, or the combination of both, or the vehicle
Result:	Combination of Cisplatin and Nrf2-IN-3 strongly inhibited the growth of A549ctl xenograft, while Cisplatin or Nrf2-IN-3 alone has no effect^[1]. Cisplatin alone or in combination with Nrf2-IN-3 significantly inhibited the growth of A549(WT-KEAP1) xenograft, but Nrf2-IN-3 did not significantly enhance the efficacy of cisplatin against this WT-KEAP1 tumor^[1]. Cisplatin alone caused slight, but significant, weight loss, Nrf2-IN-3 did not enhance Cisplatin toxicity. Nrf2-IN-3 alone or in combination with Cisplatin significantly decreased the levels of the NRF2 protein in the A549ctl tumors but not in the A549 (WT-KEAP1) tumors.

References

[1] Aboulkassim T, et al. A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants. Cell Rep. 2023 Sep 12;42(9):113104. DOI:10.1016/j.celrep.2023.113104

Spectrum Detail

Supplier

Shanghai Chaolan Chemical Technology Center

TelephoneQQ：65489617 13301690235

Websitehttp://www.atkchemical.com/

ShangHai ChuanQian Chemcial Technique Centre

Telephone 15869524721

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList68594/0_EN.htm

Bide Pharmatech Ltd.

Telephone400-1647117 13681763483

Websitehttps://www.bidepharm.com/

Wuhan Jingkangen Biomedical Technology Co., Ltd

Telephone13720134139 086-15871494362 13720134139

Websitehttps://www.jknbiochem.com

TargetMol Chemicals Inc.

Telephone 15002134094

Websitehttps://www.targetmol.cn/

Aikon International Limited

Telephone025-58851090 19370895928

Websitehttps://www.aikonchem.com/

Shandong Quadristar Material Technology Co., Ltd

Telephone 18173438764

Websitehttps://www.quadristar-sd.com.cn

Shanghai Weijiahe Biotechnology Co., Ltd

Telephone17502176150; 17502176150

Website

Shanghai meikai technology co., ltd

Telephone021-68689288 15300790979

Websitehttps://www.mkbio.com.cn/

ACME BIOPHARMA CO., LTD.

Telephone19071409695 19071409695

Website

1of2

Related Products

Send Inquriy